FDA clinical hold

RGNX faces class action lawsuit alleging false statements about RGX-111 safety. FDA clinical hold imposed after trial participant developed tumor.

Pomerantz Law Firm files class action suit against $RGNX after FDA clinical hold on gene therapy candidates triggers 17.9% stock collapse. Investor deadline: April 14, 2026.

REGENXBIO faces class action lawsuit after FDA halted RGX-111 gene therapy trial due to CNS tumor, triggering 18% stock decline.

Law firm Bragar Eagel & Squire announces class actions against $PYPL and $RGNX over alleged false projections and concealed safety risks, following significant stock declines.

REGENXBIO ($RGNX) sued for alleged securities violations involving undisclosed adverse trial data on RGX-111 candidate after FDA clinical hold.

Class actions filed against $PYPL over false revenue projections and $RGENX after FDA clinical hold on gene therapy following safety concerns.

Class action lawsuits filed against PayPal for misleading revenue projections and REGENXBIO for concealing gene therapy safety concerns, both triggering significant stock declines.

FDA places partial clinical hold on MacroGenics' LINNET trial due to serious adverse events including thrombocytopenia, myocarditis, and one death. New enrollment halted.

REGENXBIO faces class action lawsuit over allegedly false safety disclosures for gene therapy RGX-111. FDA clinical hold triggered 17.8% stock drop after adverse trial findings.

REGENXBIO faces class action lawsuit alleging securities violations over failure to disclose adverse information about RGX-111 before FDA clinical hold.

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.